Fatty acid metabolism and acyl-CoA synthetases in the liver-gut axis

doi:10.4254/wjh.v13.i11.1512

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8101)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

472

WORD

235

HTML

5647

Figures (1-2)

418

Tables (1-1)

358

Sum=7130

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

364

Download

607

Sum=971

Nov 27, 2021 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Nov 27, 2021; 13(11): 1512-1533
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1512

Table 1 miRNA and compounds targeting acyl-CoA synthetases

Type	Name	Target	Mechanism	Ref.
miRNA	miR-205	ACSL4/ACSL1	Inhibition of ACSL4/ACSL1 in hepatocellular carcinoma	[155,171]
	miR-211-5p	ACSL4	Inhibition of ACSL4 in hepatocellular carcinoma	[172]
	miR-19b-1	ACSL1/ACSL4/SCD1	Inhibition of ACSL1/ACSL4/SCD1 axis in colorectal cancer	[173]
	miR-142-3p	ACSL1/ACSL4/SCD1	Inhibition of ACSL1/ACSL4/SCD1 axis in colorectal cancer	[173,174]
	miR-34c	ACSL1	Inhibition of ACSL1 and induction of liver fibrogenesis	[175]
	miR-497-5p	ACSL5	Inhibition of ACSL5 in colon cancer	[170]
Compounds	Triacsin C	ACSL1/ACSL3/ACSL4 and ACSL5¹	Inhibition of ACSL1/ACSL3/ACSL4 and ACSL5¹	[177,178]
	Roglitazone Pioglitazone Troglitazone	ACSL4	Inhibition of ACSL4	[179-181]
	Lipofermata	FATP2	Inhibition of FATP2	[191,192]
	Grassofermata	FATP2	Inhibition of FATP2	[191,193,194]
	Ursodiol chenodiol	FATP5	Inhibition of FATP5 in liver	[195]
	Fenofibrate	PPARα	Indirect activation of FATP in liver predominantly	[196,197]

¹Triacsin C is also competitive inhibitor of ACSL5 when used in higher concentration.

Citation: Ma Y, Nenkov M, Chen Y, Press AT, Kaemmerer E, Gassler N. Fatty acid metabolism and acyl-CoA synthetases in the liver-gut axis. World J Hepatol 2021; 13(11): 1512-1533
URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1512.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1512